107759-58-0

Usage

Uses

Used in Pharmaceutical Industry:
N-Succinimidyl 4-(tri-n-butylstannyl)benzoate is used as a reactant for the synthesis of urea-based GCPII inhibitors. These inhibitors play a crucial role in the development of medications targeting gastric ulcers and other gastrointestinal disorders. The compound's reactivity and specificity make it an indispensable component in the creation of effective and targeted treatments for these conditions.

InChI:InChI=1/C11H8NO4.3C4H9.Sn/c13-9-6-7-10(14)12(9)16-11(15)8-4-2-1-3-5-8;3*1-3-4-2;/h2-5H,6-7H2;3*1,3-4H2,2H3;/rC23H35NO4Sn/c1-4-7-16-29(17-8-5-2,18-9-6-3)20-12-10-19(11-13-20)23(27)28-24-21(25)14-15-22(24)26/h10-13H,4-9,14-18H2,1-3H3

Upstream product

• 107759-57-9 tri-n-butylstannyl 4-(tri-n-butylstannyl)benzoate 
• 51934-41-9 4-iodobenzoic acid ethyl ester 
• 294210-67-6 ethyl 4-(tributylstannyl)benzoate 
• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 813-19-4 bis(tri-n-butyltin) 
• 619-58-9 4-iodobenzoic acid 
• 39028-25-6 2,5-dioxopyrrolidin-1-yl 4-iodobenzoate 

Downstream Products

• 1101867-66-6 [¹²³I]-p-lodobenzoic acid succinimide ester 
• 1196658-43-1 (4-((2,5-Dioxopyrrolidin-1-yloxy)carbonyl)phenyl)(thiophen-2-yl)iodonium trifluoroacetate 
• 1207181-34-7 C₄₃H₄₈⁽¹²⁵⁾IN₃O₁₁ 
• 210224-01-4 [¹²⁴l]-N-hydroxysuccinimide benzoate 

Relevant academic research and scientific papers

Synthesis and evaluation of novel radioiodinated PSMA targeting ligands for potential radiotherapy of prostate cancer

Radioligand therapy (RLT) using prostate-specific membrane antigen (PSMA) targeting ligands is an attractive option for the treatment of Prostate cancer (PCa) and its metastases. We report herein a series of radioiodinated glutamate-urea-lysine-phenylalan

PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AS diAGNOSTIC AND RAdiONUCLIDE THERAPEUTIC AGENTS

The present disclosure relates to compounds according to Formula I. These compounds display very good binding affinities to the PSMA binding sites. They comprise a radioactive isotope or a chelating moiety that can be labeled with a radioactive metal such as [68Ga]or [177Lu]. The present disclosure also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or a complex thereof, or a pharmaceutically acceptable salt thereof.

RADIOHALIDE-LABELED TARGETED DIAGNOSTICS AND THERAPEUTICS

Disclosed are chemical entities of formula (I) wherein R1, R2 and n are defined herein, and methods of use thereof. These chemical entities are radiative emitters and are useful, e.g., as therapeutic agents for the treatment of, or as diagnostic (e.g., imaging) agents for cancers, e.g., cancers in which PARP1 is overexpressed.

FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES

An iodonium compound of formula (I): where RAR1 is a C5-6 aryl group, bearing at least one substituent selected from formyl, thionoacyl, acylamidocarboxy, thionoester, azo, C2-20 alkenyl, C2-20 alkynyl, and (CH

Radiohalogenated for proteins

Haloaryl compounds bearing a defined functional group or precursor are metalated with either Sn(n-Bu)3 or SnMe3. The resulting aryltin compound may be transmetalated in site-specific reaction with one of the following organometallic